Merck & Co's disclosure of US pricing hints at more Trump trepidation

31 January 2017

Merck & Co (NYSE: MRK) has released information on its average annual price increases since 2010.

This move from one of the USA’s biggest pharma players follows the launch of a PR campaign by US trade group the Pharmaceutical and Research Manufacturers of America (PhRMA) to champion the achievements of the industry.

That campaign was seen as a direct response to President Donald Trump’s combative remarks on drug prices, and now Merck too is stressing that it is not one of those guilty of ripping off patients or the US healthcare system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK